Many Young Asthma Patients Noncompliant With COVID-19 Measures
TUESDAY, Dec. 15, 2020 -- A substantial percentage of young patients with asthma do not comply with COVID-19 prevention measures, according to a Mexican study recently published in the Journal of Asthma.
Francisco Vázquez-Nava, Ph.D., from the University of Tamaulipas in Tampico, Mexico, and colleagues surveyed 2,372 participants (aged 16 to 24 years) to assess risk factors that limit the adherence of asthmatic patients to COVID-19 prevention measures.
The researchers found that the prevalence of asthma was 12.2 percent and nonadherence to COVID-19 prevention guidelines was 53.1 percent. Even among patients with asthma, approximately 30.8 percent did not comply with the basic prevention measures for COVID-19. Being male, active smoking, and believing that COVID-19 is not a more severe disease for people suffering from asthma than others were associated with nonadherence to COVID-19 prevention measures.
"It is important for health professionals to advise asthma patients to comply with the basic measures of protection against COVID-19 and timely use of medications for asthma control," the authors write.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Further Support and Information on COVID-19
Read this next
FRIDAY, Jan. 22, 2021 -- Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome...
FRIDAY, Jan. 22, 2021 -- There was a decrease in the total number of pediatric emergency department visits in 2020, but the proportion of trauma-related visits increased,...
THURSDAY, Jan. 21, 2021 -- Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.